Q2 Earnings Forecast for TG Therapeutics Issued By B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at B. Riley issued their Q2 2025 earnings per share (EPS) estimates for TG Therapeutics in a note issued to investors on Tuesday, March 4th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will post earnings of $0.27 per share for the quarter. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics’ Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.28 EPS, FY2025 earnings at $1.03 EPS, FY2027 earnings at $2.78 EPS, FY2028 earnings at $3.85 EPS and FY2029 earnings at $4.74 EPS.

Several other equities analysts also recently weighed in on TGTX. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday. JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. Finally, StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $38.44 on Friday. The company has a market capitalization of $5.98 billion, a PE ratio of -384.36 and a beta of 2.30. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The business’s fifty day moving average is $30.95 and its 200 day moving average is $28.43. TG Therapeutics has a fifty-two week low of $12.93 and a fifty-two week high of $38.58.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million.

Insider Activity

In other news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently made changes to their positions in TGTX. Private Advisor Group LLC increased its holdings in shares of TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after purchasing an additional 542 shares during the last quarter. New York State Teachers Retirement System bought a new stake in shares of TG Therapeutics in the third quarter worth about $1,004,000. Amalgamated Bank increased its holdings in shares of TG Therapeutics by 712.0% in the third quarter. Amalgamated Bank now owns 39,528 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 34,660 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Finally, Los Angeles Capital Management LLC increased its holdings in shares of TG Therapeutics by 33.7% in the third quarter. Los Angeles Capital Management LLC now owns 123,401 shares of the biopharmaceutical company’s stock worth $2,886,000 after purchasing an additional 31,124 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.